SI1362590T1 - Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure - Google Patents

Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Info

Publication number
SI1362590T1
SI1362590T1 SI200230008T SI200230008T SI1362590T1 SI 1362590 T1 SI1362590 T1 SI 1362590T1 SI 200230008 T SI200230008 T SI 200230008T SI 200230008 T SI200230008 T SI 200230008T SI 1362590 T1 SI1362590 T1 SI 1362590T1
Authority
SI
Slovenia
Prior art keywords
cilobradine
prevention
treatment
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
SI200230008T
Other languages
English (en)
Slovenian (sl)
Inventor
Brian Guth Dr.
Randolf Seidler Dr.
J�rgen D�MMGEN Dr.
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1362590(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of SI1362590T1 publication Critical patent/SI1362590T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200230008T 2002-07-25 2002-07-25 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure SI1362590T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016602A EP1362590B1 (en) 2002-07-25 2002-07-25 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Publications (1)

Publication Number Publication Date
SI1362590T1 true SI1362590T1 (en) 2004-04-30

Family

ID=29265956

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200230008T SI1362590T1 (en) 2002-07-25 2002-07-25 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
SI200332021T SI1534296T1 (sl) 2002-07-25 2003-07-21 Uporaba cilobradina ali njegovih farmacevtsko sprejemljivih soli za zdravljenje ali preprečevanje odpovedi srca

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200332021T SI1534296T1 (sl) 2002-07-25 2003-07-21 Uporaba cilobradina ali njegovih farmacevtsko sprejemljivih soli za zdravljenje ali preprečevanje odpovedi srca

Country Status (29)

Country Link
US (1) US20130317008A1 (xx)
EP (2) EP1362590B1 (xx)
JP (3) JP2005533853A (xx)
KR (1) KR20050074432A (xx)
CN (1) CN100502874C (xx)
AR (1) AR040690A1 (xx)
AT (2) ATE257384T1 (xx)
AU (1) AU2003254554B8 (xx)
BR (1) BR0312852A (xx)
CA (1) CA2493208C (xx)
CO (1) CO5700723A2 (xx)
CY (1) CY1112173T1 (xx)
DE (1) DE60200160T2 (xx)
DK (2) DK1362590T3 (xx)
ES (2) ES2211846T3 (xx)
HR (1) HRP20050075B1 (xx)
MX (1) MXPA05000617A (xx)
MY (1) MY128529A (xx)
NZ (1) NZ538424A (xx)
PE (1) PE20040706A1 (xx)
PL (1) PL214716B1 (xx)
PT (2) PT1362590E (xx)
SA (1) SA03240350B1 (xx)
SI (2) SI1362590T1 (xx)
TR (1) TR200400127T4 (xx)
TW (1) TWI319321B (xx)
UY (1) UY27910A1 (xx)
WO (1) WO2004011006A1 (xx)
ZA (1) ZA200500084B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1362590T3 (da) * 2002-07-25 2004-03-29 Boehringer Ingelheim Pharma Anvendelse af cilobradin eller farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1917979A4 (en) * 2005-08-23 2009-06-03 Astellas Pharma Inc THERAPEUTICS FOR PREVIOUS LIVING ROOMS
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2927538B1 (fr) 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
EP2741736B1 (en) 2011-08-12 2017-11-22 Boehringer Ingelheim Vetmedica GmbH Taste masked pharmaceutical composition
EP2953612A1 (en) 2013-02-11 2015-12-16 Boehringer Ingelheim Vetmedica GmbH Kit-of-parts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) * 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
JP4240173B2 (ja) * 1998-06-03 2009-03-18 日産化学工業株式会社 インダン誘導体
DE60009287T2 (de) * 1999-06-03 2005-02-17 Yamanouchi Pharmaceutical Co., Ltd. Neuartige isoquinolin-derivate oder salze davon
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
DK1362590T3 (da) * 2002-07-25 2004-03-29 Boehringer Ingelheim Pharma Anvendelse af cilobradin eller farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt

Also Published As

Publication number Publication date
JP2005533853A (ja) 2005-11-10
CO5700723A2 (es) 2006-11-30
NZ538424A (en) 2006-10-27
SI1534296T1 (sl) 2011-09-30
DE60200160D1 (de) 2004-02-12
AR040690A1 (es) 2005-04-13
DK1534296T3 (da) 2011-08-15
ATE510543T1 (de) 2011-06-15
EP1362590B1 (en) 2004-01-07
TW200412974A (en) 2004-08-01
DE60200160T2 (de) 2004-11-04
ATE257384T1 (de) 2004-01-15
CN100502874C (zh) 2009-06-24
CY1112173T1 (el) 2015-12-09
PT1534296E (pt) 2011-08-18
TR200400127T4 (tr) 2004-02-23
UY27910A1 (es) 2004-02-27
PL372993A1 (en) 2005-08-08
US20130317008A1 (en) 2013-11-28
PT1362590E (pt) 2004-05-31
EP1362590A8 (en) 2004-02-25
EP1362590A1 (en) 2003-11-19
HRP20050075A2 (en) 2005-12-31
MXPA05000617A (es) 2005-08-19
AU2003254554B8 (en) 2009-02-26
JP2013166781A (ja) 2013-08-29
BR0312852A (pt) 2005-04-19
CA2493208A1 (en) 2004-02-05
MY128529A (en) 2007-02-28
DK1362590T3 (da) 2004-03-29
AU2003254554A1 (en) 2004-02-16
KR20050074432A (ko) 2005-07-18
AU2003254554B2 (en) 2009-01-29
JP2009256379A (ja) 2009-11-05
CA2493208C (en) 2011-11-01
ES2211846T3 (es) 2004-07-16
WO2004011006A1 (en) 2004-02-05
TWI319321B (en) 2010-01-11
ZA200500084B (en) 2005-10-26
PL214716B1 (pl) 2013-09-30
HRP20050075B1 (hr) 2013-12-20
CN1671392A (zh) 2005-09-21
PE20040706A1 (es) 2004-12-06
SA03240350B1 (ar) 2007-10-29
ES2367109T3 (es) 2011-10-28
EP1534296A1 (en) 2005-06-01
EP1534296B1 (en) 2011-05-25

Similar Documents

Publication Publication Date Title
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
HK1073997A1 (en) Administration of agents for the treatment of inflammation
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
HK1084037A1 (en) Medicament for treating severe heart failure
PL375964A1 (en) Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis
PL1835907T3 (pl) Leki do leczenia lub zapobiegania chorobom zwłóknieniowym
PT1530466E (pt) Utilização de nintedanib para o tratamento de fibrose pulmonar
PT1487828E (pt) Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
SI1534296T1 (sl) Uporaba cilobradina ali njegovih farmacevtsko sprejemljivih soli za zdravljenje ali preprečevanje odpovedi srca
EP1406648A4 (en) USE OF ANGIOTENSIN I DERIVATIVE AGENT FOR THE TREATMENT AND PREVENTION OF INFECTIOUS HEART DAMAGE AND DISEASES
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU1522101A (en) Heparanase inhibitors for the treatment of heart failure
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
PL369849A1 (en) Inhibition of tristetraproline for protection of the heart from cardiac injuries
HRP20041159A2 (en) Combination for the treatment of airway disorders
SI1408977T1 (sl) Kombinacijska terapija za zdravljenje srcne insuficence
AU2003257591A1 (en) Preventive and/or therapeutic agent for heart failure
AU2002345140A1 (en) A combination therapy for the treatment of heart failure
ZA200308216B (en) Medicament for the treatment of immuno-deficiency conditions.
IL164388A0 (en) Use of ranolazine for the preparation of a medicament for the treatment of arrhymias
PL354698A1 (en) Pharmaceutical compound for prevention or treatment of self-immunization based diseases
AU2003207275A1 (en) Preventive and/or therapeutic agent for cardiac disorder